Evidence map›Paper›PMID 34593911›Full record

ArticleScientific reports2021

Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus.

Travis K Warren, Christopher D Kane, Jay Wells, Kelly S Stuthman, Sean A Van Tongeren, Nicole L Garza, Ginger Donnelly, Jesse Steffens, Laura Gomba, Jessica M Weidner and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Travis K WarrenUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
Christopher D KaneUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
Jay WellsUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
Kelly S StuthmanUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
Sean A Van TongerenUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
Nicole L GarzaUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
Ginger DonnellyUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
Jesse SteffensUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
Laura GombaUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
Jessica M WeidnerUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
Sarah NorrisUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
Xiankun ZengUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA. xiankun.zeng.civ@mail.mil.
Roy BannisterGilead Sciences, Foster City, CA, 94404, USA.
Tomas CihlarGilead Sciences, Foster City, CA, 94404, USA.
Sina BavariUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA.
Danielle P PorterGilead Sciences, Foster City, CA, 94404, USA.
Patrick L IversenUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, 21702, USA. piversen@genevausa.org.
United States Army Medical Research Institute of Infectious Diseases · USThe Geneva Foundation · USGilead Sciences (United States) · US

Funding

US Army Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Defense Medical under W911QY-16-9-0001
6 · The paper itself

Abstract

Efficacious therapeutics for Ebola virus disease are in great demand. Ebola virus infections mediated by mucosal exposure, and aerosolization in particular, present a novel challenge due to nontypical massive early infection of respiratory lymphoid tissues. We performed a randomized and blinded study to compare outcomes from vehicle-treated and remdesivir-treated rhesus monkeys in a lethal model of infection resulting from aerosolized Ebola virus exposure. Remdesivir treatment initiated 4 days after exposure was associated with a significant survival benefit, significant reduction in serum viral titer, and improvements in clinical pathology biomarker levels and lung histology compared to vehicle treatment. These observations indicate that remdesivir may have value in countering aerosol-induced Ebola virus disease.

Indexed as

Adenosine MonophosphateAdministration, IntravenousAerosolsAlanineAnimalsAntiviral AgentsDisease Models, AnimalEbolavirusFemaleHemorrhagic Fever, EbolaKaplan-Meier EstimateLiverLungLymph NodesMacaca mulattaMaleAdenosine MonophosphateAerosolsAlanineAntiviral Agentsremdesivir

Identifiers

PMID34593911
PMCPMC8484580
OpenAlexW3202210957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.